Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: Area51 who wrote (617)	12/6/2021 4:59:41 PM
From: scaram(o)uche	1 Recommendation Recommended By Area51 Respond to of 684

I bought a few YMTX this morning, when it dipped well below cash. Cash is needed, however, and there's debt. Addressing large markets, down about 80% on the year. Looks like a fund bailed this morning? Came public via reverse merge and has been relegated to garbage pile. A Merck deal could provide some non-dilutive cash, but not much, if any, for near-term. Most advanced Merck project was in lead optimization about a year ago. A program transitioning to phase II for Parkinson's disease on biomarker results (without demonstration of efficacy) in phase I. Many targets looking for a candidate molecule. I like management, but nobody else seems to. I'll look at BCEL, thanks.